MedTrace Logo

Study Evaluating the Effect of Jublia on Dermatophytomas

NCT03098615 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-12-10

Study results available
· View outcomes & findings →

Summary

This study will examine how Jublia affects dermatophytomas, which are difficult to treat with other therapeutic options.

Conditions

  • Onychomycosis
  • Dermatophytosis

Interventions

DRUG

Jublia (Efinaconazole 10% Topical Solution)

Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Boni E Elewski, MD · University of Alabama at Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-05-31
Completion
2018-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03098615 on ClinicalTrials.gov